Sugi Predict

Sugi Predict / Compounds / SCHEMBL525671

SCHEMBL525671

SCHEMBL525671

CN(CCC(O)c1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.51
▸ GPR88 Q9GZN0 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ GBA1 P04062 1/20 0.41
▸ AOC3 Q16853 1/20 0.41
▸ PPARG P37231 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ PDK2 Q15119 1/20 0.40
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNB4 P30926 1/20 0.40
▸ CHRNA3 P32297 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ HTR2C P28335 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6050417 1.00 RIPK1 (0.51) RIPK1GPR88KDM4EATMGBA1
SCHEMBL6050532 1.00 RIPK1 (0.51) RIPK1GPR88KDM4EATMGBA1
SCHEMBL17267504 0.92 RIPK1 (0.49) RIPK1GPR88KDM4EATMGBA1
SCHEMBL18551012 0.85 HIF1A (0.43) RIPK1GPR88KDM4EPDK2LMNA
SCHEMBL3722932 0.85 AOC3 (0.50) RIPK1KDM4EATMAOC3SLC6A4
SCHEMBL20611086 0.85 AOC3 (0.50) RIPK1KDM4EATMAOC3SLC6A4
SCHEMBL23699370 0.84 GPR88 (0.43) RIPK1GPR88KDM4EATMGBA1
SCHEMBL1529719 0.84 GPR88 (0.43) RIPK1GPR88KDM4EATMGBA1
SCHEMBL21853987 0.84 GPR88 (0.43) RIPK1GPR88KDM4EATMGBA1
SCHEMBL499535 0.84 RIPK1 (0.38) RIPK1AOC3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678628-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS Connecta Theapeutics, S.L. (ES) 2026-01-14 — — EP disclosed
US-11401270-B2 Alcoxyamino derivatives for treating pain and pain related conditions ESTEVE PHARMACEUTICALS, S.A. (ES) 2022-08-02 — — US disclosed
US-9980928-B2 Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2018-05-29 — — US disclosed
US-9980928-B2 Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2018-05-29 — — US disclosed
US-20170239197-A1 HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2017-08-24 — — US disclosed
US-20170239197-A1 HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2017-08-24 — — US disclosed
US-20170239197-A1 HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2017-08-24 — — US disclosed
US-9624158-B2 Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2017-04-18 — — US disclosed
US-9624158-B2 Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2017-04-18 — — US disclosed
US-9624158-B2 Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) 2017-04-18 — — US disclosed
CN-101646427-A Inhibitors of akt activity SMITHKLINE BEECHAM CORP US 2010-02-10 — — CN disclosed
US-20090209607-A1 INHIBITORS OF AKT ACTIVITY NOVARTIS AG (CH) 2009-08-20 — — US disclosed
US-20090209607-A1 INHIBITORS OF AKT ACTIVITY NOVARTIS AG (CH) 2009-08-20 — — US disclosed
CN-101277933-A Substituted propylamine derivatives and methods of their use WYETH CORP (US) 2008-10-01 — — CN disclosed
WO-2008098104-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-08-14 — — WO disclosed
CN-1235870-C Novel use of phenyl hetero alkylamine derivatives ASTRAZENECA AB (SE) 2006-01-11 — — CN disclosed
US-6887871-B2 Use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2005-05-03 — — US disclosed
EP-1263711-B1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2004-12-15 — — EP disclosed
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2003-08-21 — — US disclosed
CN-1411435-A Novel use of phenylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2003-04-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209607-A1 INHIBITORS OF AKT ACTIVITY AKT2, AKT1, AKT3 RIPK1 218/4885GPR88 1262/4885KDM4E 1398/4885
US-20170239197-A1 HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES SLC1A2, PNMT, DBH RIPK1 4858/4885GPR88 246/4885KDM4E 498/4885
US-11401270-B2 Alcoxyamino derivatives for treating pain and pain related conditions CACNA1B, CACNA1G, CACNA2D2 RIPK1 4860/4885GPR88 685/4885KDM4E 2858/4885
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives NOS1, XDH, NOS2 RIPK1 3348/4885GPR88 2270/4885KDM4E 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.